dpp4 vs sglt2 vs glp-1 𝐋𝐚𝐭𝐞𝐬𝐭 𝐩𝐨𝐬𝐢𝐭𝐢𝐨𝐧 𝐨𝐟 𝐃𝐏𝐏-𝟒 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬 (𝐞.𝐠., 𝐬𝐢𝐭𝐚𝐠𝐥𝐢𝐩𝐭𝐢𝐧, 𝐬𝐚𝐱𝐚𝐠𝐥𝐢𝐩𝐭𝐢𝐧, 𝐥𝐢𝐧𝐚𝐠𝐥𝐢𝐩𝐭𝐢𝐧, 𝐚𝐥𝐨𝐠𝐥𝐢𝐩𝐭𝐢𝐧, 𝐯𝐢𝐥𝐝𝐚𝐠𝐥𝐢𝐩𝐭𝐢𝐧) 𝐢𝐧 𝐭𝐡𝐞 𝟐𝟎𝟐𝟓 𝐀𝐃𝐀 𝐒𝐭𝐚𝐧𝐝𝐚𝐫𝐝𝐬 𝐨𝐟 DPP4 degrade the GLP1 and

10.1016/j.pbb.2017.07.014 66 ThomsenM.HolstJ

Understanding your genetic profile reveals whether you need stricter sugar limitation or can tolerate occasional intake based on your individual peptide activation patterns

The Food and Drug Administration (FDA) has approved Eli Lillys Foundayo (orforglipron), a once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist, which offers a noninjectable option for weight management

In one placebo-controlled 20-week trial, those taking a daily dose of 1.2 mg of liraglutide lost an average of about 11 lb, while those on 3 mg lost, on average, about 16 lb

Potential evening downsides The biggest risk with evening dosing is forgetting